Inactivated and subunit vaccines to prevent shigellosis.
Shigellosis remains a formidable disease globally, with children of the developing world bearing the greatest number of infections. The need for an affordable, safe and efficacious vaccine has persisted for decades. Vaccines to prevent shigellosis can be divided into living and nonliving approaches. Several nonliving Shigella vaccines are currently at different stages of development and show substantial promise. Outlined here is an overview of multiple nonliving vaccine technologies, highlighting their current status and recent advances in testing. In addition, gaps in the knowledge base regarding immune mechanisms of protection are explored.
Kaminski
Robert W
RW
Division of Bacterial and Rickettsial Diseases, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
Oaks
Edwin V
EV
D001426:Bacterial Proteins / Q000276:immunology; D004405:Dysentery, Bacillary / Q000517:prevention & control*; D006801:Humans; D008070:Lipopolysaccharides / Q000276:immunology; D022281:Shigella Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D012762:Shigella dysenteriae / Q000276:immunology; D012763:Shigella flexneri / Q000276:immunology; D012764:Shigella sonnei / Q000276:immunology; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
D001426:Bacterial Proteins; D008070:Lipopolysaccharides; D022281:Shigella Vaccines; D015164:Vaccines, Inactivated; D022223:Vaccines, Subunit; C087447:ipaB protein, Shigella